financetom
Business
financetom
/
Business
/
Market Chatter: Johnson & Johnson Among Firms in Talks for Rights to Shanghai Henlius Experimental Cancer Drug
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Johnson & Johnson Among Firms in Talks for Rights to Shanghai Henlius Experimental Cancer Drug
Sep 16, 2025 4:13 AM

06:54 AM EDT, 09/16/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) and Roche are among the firms in discussions with Shanghai Henlius Biotech to buy the rights to its HLX43 experimental cancer drug, Bloomberg News reported Tuesday, citing people familiar with the matter.

If the deal goes through, the Shanghai Fosun Pharmaceutical unit could receive at least several hundred million dollars up front, with potentially more in milestone payments depending on the drug's performance, the unnamed sources told the news outlet.

HLX43 is in mid-stage testing in China, according to the report.

Johnson & Johnson ( JNJ ), Roche, and Shanghai Henlius Biotech didn't immediately respond to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AllianceBernstein Reports Increase in June Assets Under Management
AllianceBernstein Reports Increase in June Assets Under Management
Jul 10, 2025
04:37 PM EDT, 07/10/2025 (MT Newswires) -- AllianceBernstein ( AB ) said Thursday its preliminary assets under management rose to $829 billion at the end of June from $803 billion a month earlier. The increase was mainly driven by market appreciation, coupled with modest net inflows, the company said. Institutional net inflows were partially offset by net outflows from retail...
E2open Fiscal Q1 Loss Narrows, Revenue Rises; Fiscal 2026 Guidance Reiterated
E2open Fiscal Q1 Loss Narrows, Revenue Rises; Fiscal 2026 Guidance Reiterated
Jul 10, 2025
04:37 PM EDT, 07/10/2025 (MT Newswires) -- E2open Parent Holdings ( ETWO ) reported a fiscal Q1 loss late Thursday of $0.05 per diluted share, narrower than a loss of $0.13 a year earlier. One analyst surveyed by FactSet expected a loss of $0.05. Revenue for the quarter ended May 31 was $152.6 million, up from $151.2 million a year...
Salesforce Insider Sold Shares Worth $611,309, According to a Recent SEC Filing
Salesforce Insider Sold Shares Worth $611,309, According to a Recent SEC Filing
Jul 10, 2025
04:49 PM EDT, 07/10/2025 (MT Newswires) -- Marc Benioff, Director, Chair and CEO, on July 09, 2025, sold 2,250 shares in Salesforce ( CRM ) for $611,309. Following the Form 4 filing with the SEC, Benioff has control over a total of 21,969,457 common shares of the company, with 11,862,457 shares held directly and 10,107,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1108524/000112760225019080/xslF345X05/form4.xml...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved